Today, the Federal Trade Commission filed a lawsuit against three major pharmacy benefit managers (PBMs), alleging illegal, anticompetitive activity that artificially increased the price of insulin.
For years, Breakthrough T1D has advocated to federal policymakers about the urgent need to address the complex and uncertain insulin market. Insulin should be accessible to all people with type 1 diabetes at a low, predictable out-of-pocket cost.
We welcome this action to address the critical issue of affordable insulin. While the impact of today’s suit remains to be seen, we will continue to work with all stakeholders, including policymakers, to ensure that everyone has access to affordable insulin and that policies continue to support innovation and the development of newer and better insulins.
